Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients - Nasdaq

Aptevo Therapeutics Launches New 3000 IU IXINITY Assay Offering Enhanced User Experience and Improved Convenience for Hemophilia B Patients  Nasdaq

Expands Options for Patients with Potential for Reduced Reconstitution Time and Infusion Volume. SEATTLE, June 25, 2019-- Aptevo Therapeutics Inc.,.